Lurbinectedin is a chemotherapy drug used to treat patients with small cell lung cancer (SCLC). It works by inhibiting the activity of RNA polymerase II, a key enzyme in the transcription process of DNA to RNA [1]. As with most chemotherapy drugs, lurbinectedin has potential side effects that can affect various parts of the body, including the white blood cells.

According to the official website of Zepzelca, the brand name of lurbinectedin, the most common side effects of the drug include low white blood cell count, fatigue, increased creatinine levels, increased liver enzymes, nausea, decreased appetite, musculoskeletal pain, and vomiting [2]. A low white blood cell count, also known as neutropenia, can increase the risk of infection. Patients taking lurbinectedin may also experience anemia, which can cause fatigue and shortness of breath.

The Mayo Clinic also lists low white blood cell count as a potential side effect of lurbinectedin. They recommend patients who experience fever, chills, sore throat, or other signs of infection to contact their healthcare provider immediately [3].

It is important to note that not all patients will experience these side effects, and the severity of the side effects can vary from patient to patient. Patients should discuss the potential side effects of lurbinectedin with their healthcare provider before starting treatment.

In conclusion, lurbinectedin has potential side effects that can affect the white blood cells, including low white blood cell count and anemia. Patients taking lurbinectedin should be aware of these potential side effects and contact their healthcare provider if they experience any symptoms of infection or other side effects.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.zepzelca.com/zepzelca-side-effects/
[3] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1